HRP20231399T1 - Fcrn antitijela i načini njihove uporabe - Google Patents
Fcrn antitijela i načini njihove uporabe Download PDFInfo
- Publication number
- HRP20231399T1 HRP20231399T1 HRP20231399TT HRP20231399T HRP20231399T1 HR P20231399 T1 HRP20231399 T1 HR P20231399T1 HR P20231399T T HRP20231399T T HR P20231399TT HR P20231399 T HRP20231399 T HR P20231399T HR P20231399 T1 HRP20231399 T1 HR P20231399T1
- Authority
- HR
- Croatia
- Prior art keywords
- isolated antibody
- syndrome
- disease
- host cell
- autoimmune
- Prior art date
Links
- 101150050927 Fcgrt gene Proteins 0.000 title 1
- 102000039446 nucleic acids Human genes 0.000 claims 6
- 108020004707 nucleic acids Proteins 0.000 claims 6
- 150000007523 nucleic acids Chemical class 0.000 claims 6
- 208000023275 Autoimmune disease Diseases 0.000 claims 4
- 208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 claims 4
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims 4
- 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 claims 4
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims 3
- 230000028993 immune response Effects 0.000 claims 3
- 206010025135 lupus erythematosus Diseases 0.000 claims 3
- 208000011580 syndromic disease Diseases 0.000 claims 3
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims 2
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims 2
- 208000001640 Fibromyalgia Diseases 0.000 claims 2
- 208000005777 Lupus Nephritis Diseases 0.000 claims 2
- 206010034277 Pemphigoid Diseases 0.000 claims 2
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 2
- 230000004913 activation Effects 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims 2
- 208000007475 hemolytic anemia Diseases 0.000 claims 2
- 206010028417 myasthenia gravis Diseases 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 201000003068 rheumatic fever Diseases 0.000 claims 2
- 208000026872 Addison Disease Diseases 0.000 claims 1
- 208000008190 Agammaglobulinemia Diseases 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 claims 1
- 206010003267 Arthritis reactive Diseases 0.000 claims 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims 1
- 208000000659 Autoimmune lymphoproliferative syndrome Diseases 0.000 claims 1
- 208000023328 Basedow disease Diseases 0.000 claims 1
- 208000009137 Behcet syndrome Diseases 0.000 claims 1
- 208000009299 Benign Mucous Membrane Pemphigoid Diseases 0.000 claims 1
- 201000002829 CREST Syndrome Diseases 0.000 claims 1
- 208000031229 Cardiomyopathies Diseases 0.000 claims 1
- 208000031976 Channelopathies Diseases 0.000 claims 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims 1
- 208000015943 Coeliac disease Diseases 0.000 claims 1
- 208000011038 Cold agglutinin disease Diseases 0.000 claims 1
- 206010009868 Cold type haemolytic anaemia Diseases 0.000 claims 1
- 206010056370 Congestive cardiomyopathy Diseases 0.000 claims 1
- 241000699802 Cricetulus griseus Species 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 208000019707 Cryoglobulinemic vasculitis Diseases 0.000 claims 1
- 206010011878 Deafness Diseases 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 201000010046 Dilated cardiomyopathy Diseases 0.000 claims 1
- 208000007465 Giant cell arteritis Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims 1
- 208000015023 Graves' disease Diseases 0.000 claims 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims 1
- 206010020983 Hypogammaglobulinaemia Diseases 0.000 claims 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 1
- 208000010159 IgA glomerulonephritis Diseases 0.000 claims 1
- 206010021263 IgA nephropathy Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 1
- 201000003088 Limited Scleroderma Diseases 0.000 claims 1
- 208000024140 Limited cutaneous systemic sclerosis Diseases 0.000 claims 1
- 208000027530 Meniere disease Diseases 0.000 claims 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims 1
- 208000003250 Mixed connective tissue disease Diseases 0.000 claims 1
- 208000012192 Mucous membrane pemphigoid Diseases 0.000 claims 1
- 201000011152 Pemphigus Diseases 0.000 claims 1
- 208000031845 Pernicious anaemia Diseases 0.000 claims 1
- 206010065159 Polychondritis Diseases 0.000 claims 1
- 208000007048 Polymyalgia Rheumatica Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 208000012322 Raynaud phenomenon Diseases 0.000 claims 1
- 208000033464 Reiter syndrome Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 206010072148 Stiff-Person syndrome Diseases 0.000 claims 1
- 208000001106 Takayasu Arteritis Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 206010047642 Vitiligo Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 208000004631 alopecia areata Diseases 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 208000000594 bullous pemphigoid Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims 1
- 201000010002 cicatricial pemphigoid Diseases 0.000 claims 1
- 201000003278 cryoglobulinemia Diseases 0.000 claims 1
- 230000001086 cytosolic effect Effects 0.000 claims 1
- 201000001981 dermatomyositis Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 claims 1
- 230000010370 hearing loss Effects 0.000 claims 1
- 231100000888 hearing loss Toxicity 0.000 claims 1
- 208000016354 hearing loss disease Diseases 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 208000003532 hypothyroidism Diseases 0.000 claims 1
- 230000002989 hypothyroidism Effects 0.000 claims 1
- 208000015557 immune complex mediated vasculitis Diseases 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 1
- 201000011486 lichen planus Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims 1
- 108010068617 neonatal Fc receptor Proteins 0.000 claims 1
- 208000008795 neuromyelitis optica Diseases 0.000 claims 1
- 208000004235 neutropenia Diseases 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 201000001976 pemphigus vulgaris Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 201000006292 polyarteritis nodosa Diseases 0.000 claims 1
- 208000005987 polymyositis Diseases 0.000 claims 1
- 208000002574 reactive arthritis Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- 206010040400 serum sickness Diseases 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 206010043207 temporal arteritis Diseases 0.000 claims 1
- 206010043778 thyroiditis Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Transplantation (AREA)
- Nutrition Science (AREA)
Claims (17)
1. Izolirano antitijelo koje se vezuje za humani FcRn, izolirano antitijelo koje sadrži polipeptid koji ima aminokiselinsku sekvencu SEQ ID NO: 19 i polipeptid koji ima aminokiselinsku sekvencu SEQ ID NO: 24.
2. Farmaceutska kompozicija koja sadrži izolirano antitijelo prema patentnom zahtjevu 1 i jedan ili više farmaceutski prihvatljivih nosača ili ekscipijenasa.
3. Izolirano antitijelo prema patentnom zahtjevu 1 za uporabu u postupku smanjenja ili liječenja aktivacije akutnog imunog odgovora na bazi imunološkog kompleksa koji je aktiviran medicinskim stanjem izabranim iz grupe koja se sastoji od pemfigus vulgarisa, lupus nefritisa, mijastenije gravis, Guillain-Barre-ovog sindroma, odbacivanja posredovanog antitijelom, katastrofalnog sindroma anti-fosfolipidnih antitijela, vaskulitisa posredovanog imunim kompleksom, glomerulitisa, kanalopatije, neuromijelitis optike, autoimunog gubitka sluha, idiopatske trombocitopenije purpure (ITP), autoimune hemolitičke anemije (AIHA), imune neutropenije, dilatirane kardiomiopatije i serumske bolesti.
4. Izolirano antitijelo za uporabu prema patentnom zahtjevu 3, naznačeno time što navedeno stanje je miastenija gravis.
5. Izolirano antitijelo za uporabu prema patentnom zahtjevu 3, naznačeno time što navedeno stanje je lupus nefritis.
6. Izolirano antitijelo za uporabu prema patentnom zahtjevu 3, naznačeno time što navedeno stanje je AIHA.
7. Izolirano antitijelo prema patentnom zahtjevu 1 za uporabu u postupku smanjenja ili liječenja aktivacije kroničnog imunog odgovora zasnovanog na imunom kompleksu koji je aktiviran medicinskim stanjem izabranim iz grupe koja se sastoji od kronične upalne demijelinizirajuće polineuropatije (CIDP), sistemskog lupusa, reaktivne artropatije, primarne bilijarne ciroze, ulceroznog kolitisa i vaskulitisa povezanog sa antineutrofilnim citoplazmatskim antitijelom (ANCA).
8. Izolirano antitijelo za uporabu prema patentnom zahtjevu 7, naznačeno time što navedeno stanje je CIDP.
9. Izolirano antitijelo prema patentnom zahtjevu 1 za uporabu u postupku smanjenja ili liječenja imunog odgovora aktiviranog autoimunom bolešću.
10. Izolirano antitijelo za uporabu prema patentnom zahtjevu 9, naznačeno time što je navedena autoimuna bolest izabrana iz grupe koja se sastoji od alopecije areate, ankilozirajućeg spondilitisa, antifosfolipidnog sindroma, Addisonove bolesti, hemolitičke anemije, autoimunog hepatitisa, hepatitisa, Behcetove bolesti, buloznog pemfigoida, kardiomiopatije, celijakije sprue-dermatitisa, sindroma kroničnog umora imune disfunkcije, kronične upalne demijelinizirajuće polineuropatije, Churg-Straussovovog sindroma, cikatricijalnog pemfigoida, ograničene skleroderme (CREST sindroma), bolesti hladnog aglutinina, Crohnove bolesti, dermatomiozitisa, diskoidnog lupusa, esencijalne miješane krioglobulinemije, fibromijalgije, fibromiozitisa, Gravesove bolesti, Hashomotovog torioiditisa, hipotiroidizma, upalne bolesti crijeva, autoimunog limfoproliferativnog sindroma, idiopatske plućne fibroze, IgA nefropatije, dijabetesa zavisnog od inzulina, mladenačkog artritisa, lihen planusa, lupusa, Menierove bolesti, miješane bolesti vezivnog tkiva, multiple skleroze, perniciozne anemije, poliarteritis nodoze, polihondritisa, poliglandularnih sindroma, polimijalgije reumatike, polimiozitisa, primarne agamaglobulinemije, primarne bilijarne ciroze, psorijaze, Raynaudovog fenomena, Reiterovog sindroma, reumatske groznice, reumatskog artritisa, sarkoidoze, skleroderme, Sjogrenovog sindroma, sindroma ukočene osobe, Takayasu arteritisa, temporalnog arteritisa, ulceroznog kolitisa, uveitisa, vitiliga i Wegenerove granulomatoze.
11. Izolirano antitijelo za uporabu prema patentnom zahtjevu 10, naznačeno time što navedena autoimuna bolest je hemolitička anemija.
12. Izolirano antitijelo za uporabu prema patentnom zahtjevu 10, naznačeno time što navedena autoimuna bolest je reumatoidni artritis.
13. Molekula nukleinske kiseline koja kodira izolirano antitijelo prema patentnom zahtjevu 1.
14. Vektor koji sadrži nukleinsku kiselinu prema patentnom zahtjevu 13.
15. Stanica domaćin koja eksprimira izolirano antitijelo prema patentnom zahtjevu 1, naznačena time što stanica domaćin sadrži molekulu nukleinske kiseline prema patentnom zahtjevu 13 ili vektor prema patentnom zahtjevu 14, pri čemu je molekula ili vektor nukleinske kiseline eksprimirana u stanici domaćinu.
16. Stanica domaćin prema patentnom zahtjevu 15, naznačena time što stanica domaćin je stanica jajnika kineskog hrčka (CHO).
17. Postupak za pripremu izoliranog antitijela prema patentnom zahtjevu 1, naznačen time što postupak sadrži:
a) osiguravanje stanice domaćina koja sadrži molekulu nukleinske kiseline prema patentnom zahtjevu 13 ili vektor prema patentnom zahtjevu 14; i
b) ekspresiju navedene molekule nukleinske kiseline ili vektora u navedenoj stanici domaćinu pod uvjetima koji dozvoljavaju formiranje antitijela.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562110071P | 2015-01-30 | 2015-01-30 | |
| US201562258082P | 2015-11-20 | 2015-11-20 | |
| EP16744204.5A EP3250610B1 (en) | 2015-01-30 | 2016-01-29 | Fcrn antibodies and methods of use thereof |
| PCT/US2016/015720 WO2016123521A2 (en) | 2015-01-30 | 2016-01-29 | Fcrn antibodies and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20231399T1 true HRP20231399T1 (hr) | 2024-02-16 |
Family
ID=56544538
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20231399TT HRP20231399T1 (hr) | 2015-01-30 | 2016-01-29 | Fcrn antitijela i načini njihove uporabe |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US10676526B2 (hr) |
| EP (2) | EP4286011A3 (hr) |
| JP (2) | JP6853178B2 (hr) |
| KR (2) | KR102483016B1 (hr) |
| CN (13) | CN118667015A (hr) |
| AU (1) | AU2016211280B2 (hr) |
| CA (1) | CA2972822A1 (hr) |
| DK (1) | DK3250610T3 (hr) |
| ES (1) | ES2962824T3 (hr) |
| FI (1) | FI3250610T3 (hr) |
| HR (1) | HRP20231399T1 (hr) |
| HU (1) | HUE063778T2 (hr) |
| IL (1) | IL252837B (hr) |
| LT (1) | LT3250610T (hr) |
| NZ (1) | NZ733097A (hr) |
| PL (1) | PL3250610T3 (hr) |
| PT (1) | PT3250610T (hr) |
| RS (1) | RS64768B1 (hr) |
| SG (2) | SG10202007232WA (hr) |
| SI (1) | SI3250610T1 (hr) |
| WO (1) | WO2016123521A2 (hr) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2934644C (en) | 2013-12-24 | 2023-11-21 | Argen-X N.V. | Fcrn antagonists and methods of use |
| CA2946430A1 (en) * | 2014-06-12 | 2015-12-17 | F. Hoffmann-La Roche Ag | Method for selecting antibodies with modified fcrn interaction |
| US10676526B2 (en) | 2015-01-30 | 2020-06-09 | Momenta Pharmaceuticals, Inc. | FcRn antibodies and methods of use thereof |
| CN109790221B (zh) * | 2016-07-29 | 2023-12-26 | 动量制药公司 | Fcrn抗体及其使用方法 |
| RU2020100880A (ru) * | 2017-06-15 | 2021-07-15 | Юсб Биофарма Срл | Способ лечения иммунной тромбоцитопении |
| KR20200098604A (ko) | 2017-12-13 | 2020-08-20 | 모멘타 파머슈티컬스 인코포레이티드 | FcRn 항체 및 이의 사용 방법 |
| MX2020013195A (es) | 2018-06-08 | 2021-02-26 | Argenx Bvba | Composiciones y metodos para el tratamiento de la trombocitopenia inmunitaria. |
| JOP20210014A1 (ar) * | 2018-07-20 | 2021-01-19 | Zhongli Zhang | تركيبات مضادات fcrn وطرق استخدامها |
| WO2020018910A1 (en) * | 2018-07-20 | 2020-01-23 | Momenta Pharmaceuticals, Inc. | Fcrn antibody compositions |
| US20220144941A1 (en) | 2018-10-16 | 2022-05-12 | UCB Biopharma SRL | Method for the treatment of myasthenia gravis |
| JP7565951B2 (ja) | 2019-06-07 | 2024-10-11 | アルジェニクス ビーブイ | 皮下投与に好適なＦｃＲｎインヒビターの医薬製剤 |
| MX2022001380A (es) * | 2019-08-01 | 2022-03-25 | Momenta Pharmaceuticals Inc | Anticuerpos de fcrn y metodos de uso de los mismos. |
| IL292889A (en) * | 2019-11-19 | 2022-07-01 | Immunovant Sciences Gmbh | Methods for the treatment of warm autoimmune hemolytic anemia using anti-fcrn antibodies |
| MX2023005313A (es) * | 2020-11-06 | 2023-07-11 | Momenta Pharmaceuticals Inc | Anticuerpos fcrn y metodos de uso de estos. |
| EP4287828A1 (en) * | 2021-02-02 | 2023-12-13 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Genetically modified non-human animal with human or chimeric fcrn |
| CN116234827A (zh) * | 2021-09-03 | 2023-06-06 | 舒泰神（北京）生物制药股份有限公司 | 特异性识别FcRn的抗体及其应用 |
| AU2023281650A1 (en) | 2022-05-30 | 2024-10-17 | Hanall Biopharma Co., Ltd. | Anti-fcrn antibody or antigen binding fragment thereof with improved stability |
| WO2024163894A1 (en) | 2023-02-04 | 2024-08-08 | Momenta Pharmaceuticals, Inc. | Compositions and methods for treating hemolytic disease of the fetus and newborn |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4364645B2 (ja) | 2002-02-14 | 2009-11-18 | 中外製薬株式会社 | 抗体含有溶液製剤 |
| EP1660128A4 (en) * | 2003-08-08 | 2009-01-21 | Univ New York State Res Found | ANTI-CORR ANTI-BODIES FOR THE TREATMENT OF AUTO / ALLO-IMMUNE DISORDERS |
| US7662928B2 (en) | 2003-08-08 | 2010-02-16 | The Research Foundation Of State University Of New York | Anti-FcRn antibodies for treatment of auto/allo immune conditions |
| CN101124245A (zh) * | 2003-11-12 | 2008-02-13 | 比奥根艾迪克Ma公司 | 新生儿Fc受体(FcRn)-结合多肽变体、二聚体Fc结合蛋白及其相关方法 |
| NZ561137A (en) | 2005-03-08 | 2011-09-30 | Pharmacia & Upjohn Co Llc | Stable anti-CTLA-4 antibody compositions with chelating agents |
| CA2637929A1 (en) | 2006-01-25 | 2007-08-02 | The Research Foundation Of State University Of New York | Anti-fcrn antibodies for treatement of auto/allo immune conditions |
| CN101421297A (zh) * | 2006-02-17 | 2009-04-29 | 森托尼克斯制药有限公司 | 阻断lgG对FcRn的结合的肽 |
| CA2644405A1 (en) * | 2006-03-13 | 2007-09-20 | Ablynx N.V. | Amino acid sequences directed against il-6 and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling |
| NZ589451A (en) * | 2008-04-25 | 2012-07-27 | Dyax Corp | Antibodies against fcrn and use thereof |
| WO2011008517A2 (en) * | 2009-06-30 | 2011-01-20 | Research Development Foundation | Immunoglobulin fc polypeptides |
| AU2012262007B2 (en) * | 2011-06-02 | 2017-06-22 | Takeda Pharmaceutical Company Limited | Fc receptor binding proteins |
| GB201208370D0 (en) | 2012-05-14 | 2012-06-27 | Ucb Pharma Sa | Antibodies |
| US20130323242A1 (en) | 2012-06-01 | 2013-12-05 | Ophthotech Corp. | Compositions comprising an anti-pdgf aptamer and a vegf antagonist |
| EP2934587A4 (en) | 2012-12-18 | 2016-08-03 | Merck Sharp & Dohme | LIQUID FORMULATIONS FOR ANTI-TNFALPHA ANTIBODY |
| EP3719122A1 (en) | 2013-05-02 | 2020-10-07 | Momenta Pharmaceuticals, Inc. | Sialylated glycoproteins |
| KR101815265B1 (ko) | 2013-06-20 | 2018-01-04 | 한올바이오파마주식회사 | FcRn 특이적 인간 항체 및 이를 포함하는 자가면역 질환 치료용 조성물 |
| US10676526B2 (en) | 2015-01-30 | 2020-06-09 | Momenta Pharmaceuticals, Inc. | FcRn antibodies and methods of use thereof |
| US20160264669A1 (en) * | 2015-03-09 | 2016-09-15 | Argen-X N.V. | Methods of reducing serum levels of fc-containing agents using fcrn antagonists |
| WO2016183352A1 (en) | 2015-05-12 | 2016-11-17 | Syntimmune, Inc. | Humanized affinity matured anti-fcrn antibodies |
| CN109790221B (zh) | 2016-07-29 | 2023-12-26 | 动量制药公司 | Fcrn抗体及其使用方法 |
| WO2019110823A1 (en) | 2017-12-08 | 2019-06-13 | Argenx Bvba | Use of fcrn antagonists for treatment of generalized myasthenia gravis |
| KR20200098604A (ko) | 2017-12-13 | 2020-08-20 | 모멘타 파머슈티컬스 인코포레이티드 | FcRn 항체 및 이의 사용 방법 |
| JOP20210014A1 (ar) | 2018-07-20 | 2021-01-19 | Zhongli Zhang | تركيبات مضادات fcrn وطرق استخدامها |
| WO2020018910A1 (en) | 2018-07-20 | 2020-01-23 | Momenta Pharmaceuticals, Inc. | Fcrn antibody compositions |
-
2016
- 2016-01-29 US US15/546,870 patent/US10676526B2/en active Active
- 2016-01-29 CN CN202410661152.XA patent/CN118667015A/zh active Pending
- 2016-01-29 SG SG10202007232WA patent/SG10202007232WA/en unknown
- 2016-01-29 WO PCT/US2016/015720 patent/WO2016123521A2/en active Application Filing
- 2016-01-29 HU HUE16744204A patent/HUE063778T2/hu unknown
- 2016-01-29 KR KR1020177024165A patent/KR102483016B1/ko active IP Right Grant
- 2016-01-29 LT LTEPPCT/US2016/015720T patent/LT3250610T/lt unknown
- 2016-01-29 ES ES16744204T patent/ES2962824T3/es active Active
- 2016-01-29 CN CN202410661133.7A patent/CN118667009A/zh active Pending
- 2016-01-29 CN CN202410661150.0A patent/CN118667014A/zh active Pending
- 2016-01-29 KR KR1020227045647A patent/KR20230007545A/ko not_active Application Discontinuation
- 2016-01-29 DK DK16744204.5T patent/DK3250610T3/da active
- 2016-01-29 EP EP23189767.9A patent/EP4286011A3/en active Pending
- 2016-01-29 CN CN202410661144.5A patent/CN118562003A/zh active Pending
- 2016-01-29 AU AU2016211280A patent/AU2016211280B2/en active Active
- 2016-01-29 CN CN202410661149.8A patent/CN118667013A/zh active Pending
- 2016-01-29 CN CN202410661136.0A patent/CN118638230A/zh active Pending
- 2016-01-29 PL PL16744204.5T patent/PL3250610T3/pl unknown
- 2016-01-29 CN CN202410661140.7A patent/CN118667010A/zh active Pending
- 2016-01-29 SI SI201631739T patent/SI3250610T1/sl unknown
- 2016-01-29 RS RS20231028A patent/RS64768B1/sr unknown
- 2016-01-29 CN CN202410661147.9A patent/CN118667012A/zh active Pending
- 2016-01-29 NZ NZ733097A patent/NZ733097A/en unknown
- 2016-01-29 CN CN202410661138.XA patent/CN118652337A/zh active Pending
- 2016-01-29 SG SG11201705475QA patent/SG11201705475QA/en unknown
- 2016-01-29 FI FIEP16744204.5T patent/FI3250610T3/fi active
- 2016-01-29 EP EP16744204.5A patent/EP3250610B1/en active Active
- 2016-01-29 CA CA2972822A patent/CA2972822A1/en active Pending
- 2016-01-29 CN CN202110605791.0A patent/CN113384693A/zh active Pending
- 2016-01-29 JP JP2017539428A patent/JP6853178B2/ja active Active
- 2016-01-29 PT PT167442045T patent/PT3250610T/pt unknown
- 2016-01-29 CN CN202410661131.8A patent/CN118638229A/zh active Pending
- 2016-01-29 CN CN202410661142.6A patent/CN118667011A/zh active Pending
- 2016-01-29 CN CN201680008485.6A patent/CN107567460B/zh active Active
- 2016-01-29 HR HRP20231399TT patent/HRP20231399T1/hr unknown
-
2017
- 2017-06-11 IL IL252837A patent/IL252837B/en unknown
-
2020
- 2020-03-20 US US16/825,066 patent/US11732047B2/en active Active
-
2021
- 2021-01-12 JP JP2021002601A patent/JP7224382B2/ja active Active
-
2023
- 2023-07-13 US US18/351,827 patent/US20240158508A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20231399T1 (hr) | Fcrn antitijela i načini njihove uporabe | |
| HRP20192098T1 (hr) | Antitijela na glukokortikoidom inducirani receptor faktora nekroze tumora (gitr) i njihove primjene | |
| HRP20240048T1 (hr) | Fcrn antitijela i postupci njihove uporabe | |
| HRP20201259T1 (hr) | Protutijela protiv ox40 i njihova upotreba | |
| HRP20170815T1 (hr) | Agonisti receptora 1 fibroblastnog čimbenika rasta i postupci uporabe | |
| JP2017501725A5 (hr) | ||
| BR112018006579A2 (pt) | anticorpos anti-humanos cd19 humanizados e métodos de uso | |
| JP2017163973A5 (hr) | ||
| HRP20210844T1 (hr) | Tetrahidropiranil amino-pirolopirimidinon i postupci njegove primjene | |
| RU2018113505A (ru) | Il-8-связывающие антитела и их применения | |
| HRP20201513T1 (hr) | Cd40l-specifični tn3-izvedeni skeleti i postupci njihove uporabe | |
| HRP20170568T1 (hr) | Protutijela anti-ox40 i postupci za njihovu uporabu | |
| JP2016518823A5 (hr) | ||
| JP2017535261A5 (hr) | ||
| HRP20190752T1 (hr) | Novo protutijelo protiv ljudskog receptora tslp | |
| JP2019519527A5 (hr) | ||
| JP2017510575A5 (hr) | ||
| SI2889310T1 (en) | Formulations of antibodies | |
| JP2016509009A5 (hr) | ||
| SG10201809694PA (en) | Antibody neutralizing human respiratory syncytial virus | |
| JP2018509413A5 (hr) | ||
| JP2016540195A5 (hr) | ||
| RU2022101891A (ru) | Способы применения cd32b x cd79b-связывающих молекул при лечении воспалительных заболеваний и расстройств | |
| JP2021506786A5 (hr) | ||
| BR112021000755A2 (pt) | Composições de anticorpo de fcrn |